KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Castle Biosciences (CSTL) Consolidated Net Income (2018 - 2026)

Castle Biosciences' Consolidated Net Income history spans 8 years, with the latest figure at -$2.3 million for Q4 2025.

  • On a quarterly basis, Consolidated Net Income fell 124.32% to -$2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$24.2 million, a 232.41% decrease, with the full-year FY2025 number at -$24.2 million, down 232.41% from a year prior.
  • Consolidated Net Income hit -$2.3 million in Q4 2025 for Castle Biosciences, down from -$501000.0 in the prior quarter.
  • Over the last five years, Consolidated Net Income for CSTL hit a ceiling of $9.6 million in Q4 2024 and a floor of -$29.2 million in Q1 2023.
  • Historically, Consolidated Net Income has averaged -$8.4 million across 5 years, with a median of -$5.6 million in 2021.
  • Biggest five-year swings in Consolidated Net Income: tumbled 1039.38% in 2023 and later surged 471.71% in 2024.
  • Tracing CSTL's Consolidated Net Income over 5 years: stood at -$13.4 million in 2021, then tumbled by 54.08% to -$20.6 million in 2022, then soared by 87.49% to -$2.6 million in 2023, then surged by 471.71% to $9.6 million in 2024, then plummeted by 124.32% to -$2.3 million in 2025.
  • Business Quant data shows Consolidated Net Income for CSTL at -$2.3 million in Q4 2025, -$501000.0 in Q3 2025, and $4.5 million in Q2 2025.